Montgomery Erwin B
Center for Functional and Restorative Neuroscience, Department of Neurology, The Cleveland Clinic Foundation, Ohio 44195, USA.
Cleve Clin J Med. 2002 Aug;69(8):639-43. doi: 10.3949/ccjm.69.8.639.
Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.
在帕金森病病程早期一般应避免使用左旋多巴；多巴胺激动剂，尤其是第二代药物，如罗匹尼罗（Requip）和普拉克索（Mirapex），发生运动障碍的长期风险较小，应取而代之使用。深部脑刺激在难治性病例中效果显著，很可能开创慢性神经疾病治疗的新时代。
